Every day, scientists and specialists work hard to find new ways and formulas that help humanity in its difficult fight against the coronavirus.
The arrival and application of vaccines caused infections, hospitalizations and deaths to decrease; However, the new variants of COVID-19, especially the one known as delta, have again raised the numbers in some regions.
In fact, some cities like Los Angeles have chosen to return to the use of masks indoors and without the necessary ventilation, regardless of whether people are immunized or not.
Race for the pill against COVID-19
For these reasons, a new race is now beginning between several pharmaceutical companies to develop a treatment in the form of pills that counteracts the coronavirus.
In fact, a Japanese firm has already started clinical trials, to join giants like Pfizer and MSD (Merck Sharp & Dohme).
It is the Japanese company Shionogi, which already tests its pill with humans, which is planned to be ingested once every 24 hours in people who are infected.
“Our goal is a safe oral product, like Tamiflu, like Xofluza,” the company’s CEO, Isao Teshirogi, told The Wall Street Jorunal, referring to two drugs used against the flu.
The Japanese company that in the past has had great results with other medicines, such as one to lower cholesterol, is still behind in the way of Pfizer and MSD, which have more advanced studies on these treatments.
The pills for the coronavirus are designed for all those who have mild symptoms and are at home, unlike the treatments that have given the most results to date, such as Remdesevir, which must be administered in hospitals to the seriously ill .
Because efforts have focused on vaccines, not much progress has been made in this area over the past year.
In the case of Pfizer, the company maintains that its pill would be taken twice a day and that it is similar in design to the one made by Shionogi. They assure that it could go on the market in 2021.
While MSD uses a formula studied years ago as a possible response to Ebola. The firm mentions that it has been shown to be effective in reducing the viral load of patients with coronavirus and could reduce hospitalizations in the future.